key: cord-0682661-apcnuzv0 authors: Gu, Chenjian; Wu, Yang; Guo, Huimin; Zhu, Yuanfei; Xu, Wei; Wang, Yuyan; Zhou, Yu; Sun, Zhiping; Cai, Xia; Li, Yutang; Liu, Jing; Huang, Zhong; Yuan, Zhenghong; Zhang, Rong; Deng, Qiang; Qu, Di; Xie, Youhua title: Protoporphyrin IX and verteporfin prevent SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2 date: 2020-07-30 journal: bioRxiv DOI: 10.1101/2020.04.30.071290 sha: fae67dfc907a04c821b9f8a90aa0e7dcde55d896 doc_id: 682661 cord_uid: apcnuzv0 The SARS-CoV-2 infection is spreading rapidly worldwide. Efficacious antiviral therapeutics against SARS-CoV-2 is urgently needed. Here, we discovered that protoporphyrin IX (PpIX) and verteporfin, two FDA-approved drugs, completely inhibited the cytopathic effect produced by SARS-CoV-2 infection at 1.25 μM and 0.31 μM respectively, and their EC50 values of reduction of viral RNA were at nanomolar concentrations. The selectivity indices of PpIX and verteporfin were 952.74 and 368.93, respectively, suggesting broad margin of safety. Importantly, PpIX and verteporfin prevented SARS-CoV-2 infection in mice adenovirally transduced with human ACE2. The compounds, sharing a porphyrin ring structure, were shown to bind viral receptor ACE2 and interfere with the interaction between ACE2 and the receptor-binding domain of viral S protein. Our study suggests that PpIX and verteporfin are potent antiviral agents against SARS-CoV-2 infection and sheds new light on developing novel chemoprophylaxis and chemotherapy against SARS-CoV-2. SARS-CoV-2 is transmitted through respiratory droplets and close contact, which (Fig. 1A) , respectively. The EC50 of remdesivir was comparable to the 12 previous report 2 . Cell viability assay was performed, resulting in a viability-compound 13 concentration curve (Fig. 1A) , from which the CC50 (cytotoxicity concentration 50%) 14 values of protoporphyrin IX, verteporfin and remdesivir were determined to be 219.13 15 µM, 10.33 µM, and 303.23 µM, respectively. The selectivity indices (S.I.) for the three 16 compounds could thus be calculated as 952.74, 368.93, and 224.61, respectively. Viral 17 N protein expression in infected Vero-E6 cells was assessed by immunofluorescence. 18 The data revealed the complete inhibition of N protein expression by protoporphyrin 26 We next analyzed the relationship between the antiviral effect and treatment timing of 27 protoporphyrin IX and verteporfin. As shown in Fig. 2A , Vero-E6 cells were treated 28 with protoporphyrin IX, verteporfin or the solvent DMSO before viral infection, during Protoporphyrin IX and verteporfin interact with human ACE2 protein 23 Protoporphyrin IX and verteporfin share a same structure formed by four pyrrole rings 24 (Fig. 4A ) and thus likely act through a common antiviral mechanism. The above results 25 suggest that both drugs act by inhibiting an early step in viral infection. One possibility 26 was the saturation or modification of an essential cellular factor(s) required for viral 27 infection. We thus investigated firstly by molecular docking analysis whether human 28 ACE2, the viral receptor, might be the target of the compounds. The ACE2 peptidase 29 6 domain (PD) from the human ACE2-B 0 AT1 complex (PDB ID: 6m18) 16 was used for 1 docking with protoporphyrin IX and verteporfin (Fig. 4A ). The result with the highest 2 ranking is exhibited in Fig. 4B , which represents the molecular model of protoporphyrin 3 IX or verteporfin binding to PD. Protoporphyrin IX is located in the shallow-pocket- We next used BLI (Biolayer Interferometry) assay to evaluate the binding between 22 ACE2 and these two compounds. As shown in Fig. 4D , protoporphyrin IX and 23 verteporfin indeed bind to ACE2-Fc. The KD of protoporphyrin IX and verteporfin 24 binding to ACE2-Fc were calculated to be 3.897×10 -5 mol/L and 1.15×10 -4 mol/L, 25 respectively. Therefore, structural simulation by molecular docking and direct drug-26 protein binding assay support the binding of both drugs to viral receptor ACE2. 1 Based on the molecular docking and the experimental data, both drugs likely interfere 2 with the interaction between ACE2 and RBD via binding ACE2, which would impair 3 viral entry. We first tested this possibility using a cell-cell fusion assay. HEK293T cells 4 that express SARS-CoV-2 S protein served as the effector cells and those co-expressing 5 human ACE2 and GFP as the target cells (Fig. 5A) . The target cells were pre-treated 6 with protoporphyrin IX (2.5 μM), verteporfin (1.25 μM) or DMSO for 1 hour. After 7 removal of the drug, the target and effector cells were co-cultured at 37℃ for 4 hours. Fused cells with larger cell size than normal cells were observed in the DMSO-treated 9 group but barely in the protoporphyrin IX or verteporfin-treated group. The results 10 indicate that protoporphyrin IX and verteporfin may block interaction of ACE2 and 11 viral S protein which is required for cell-cell fusion. To more directly demonstrate the interference of the compounds with the interaction of 14 ACE2 to RBD, we designed an ELISA assay, in which protoporphyrin IX or verteporfin 15 was added to 96-well plate pre-coated with ACE2-Fc or His-RBD. After incubation, 16 unbound drugs were washed away. His-RBD or ACE2-Fc was added to the drug-treated 17 wells pre-coated with ACE2-Fc or His-RBD. The results showed that both drugs could 18 prevent the binding of His-RBD to pre-coated ACE2-Fc, while they had no effect on Both protoporphyrin IX and verteporfin have a porphyrin ring structure formed by four 26 pyrrole rings. It is most likely that they share a similar mechanism of antiviral action. In the experiment when either drug was added prior to viral infection, viral RNA In conclusion, this study has discovered protoporphyrin IX and verteporfin as potent High-titer adenovirus was purified by CsCl gradient centrifugation and virus titer was 6 determined as described previously 31 . The resulting virus stock had a titer of 4.6*10 12 7 vp/mL. 18 Viral RNA in tissue and cell supernatant was extracted using TRIzol reagent (Invitrogen, (1 g/mL) were prepared by homogenizing perfused lung tissues using an automatic 4 sample grinding instrument (Jingxin, Shanghai, China) for 1 minute in TRIzol reagent. The homogenates were centrifuged at 12,000 rpm for 10 minutes at 4 °C. The 6 supernatant was collected for viral RNA extraction. verteporfin-treated group was presented relative to that of the DMSO-treated group which was set as 100%, respectively. Statistical significance was determined using the unpaired two-tailed Student's t test. *** P < 0.001. (B) ELISA. The binding of His-RBD or ACE2-Fc to drug-treated pre-coated ACE-Fc or His-RBD was measured by absorbance at 450 nm. Statistical significance was determined using the unpaired twotailed Student's t test. *** P < 0.001. Data from triplicate wells were analyzed. Western blot analysis of hACE2 protein in HEK293T cells transduced by Ad5-hACE2. HEK293T cells were transduced with Ad5-hACE2 or Ad5-Ctrl at MOI of 100 at 37 ℃ for 4 hours. HEK293T cells without any treatment were used as negative control. Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-16 2 RNA dependent RNA polymerase (RdRp): A molecular docking study Remdesivir and chloroquine effectively inhibit the recently emerged novel 19 coronavirus (2019-nCoV) in vitro Compassionate Use of Remdesivir for Patients with Severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, 24 placebo-controlled, multicentre trial Remdesivir for the Treatment of Covid-19 -Preliminary Report Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine Favipiravir and Other Drugs for the Treatment of the New Coronavirus A Review of SARS-CoV-2 and the Ongoing Clinical Trials The FDA-approved drug 35 ivermectin inhibits the replication of SARS-CoV-2 in vitro Hydroxychloroquine for the management of COVID-6 19: Hope or Hype? A Systematic review of the current evidence. medRxiv Outcomes of hydroxychloroquine usage in United States veterans 9 hospitalized with Covid-19. medRxiv A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 12 A neutralizing human antibody binds to the N-terminal domain of the Spike protein 14 of SARS-CoV-2 A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Protoporphyrin IX: the Good, the Bad, and the Ugly Heme: emergent roles of heme in 22 signal transduction, functional regulation and as catalytic centres Heme proteins--diversity in structural 25 characteristics, function, and folding Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and 27 therapy Photodynamic therapy in oncology: mechanisms and clinical use The photobiology of photodynamic therapy: cellular targets and 31 mechanisms Mechanisms of action of photodynamic therapy with 33 verteporfin for the treatment of age-related macular degeneration Multifunctional theranostic Pluronic mixed micelles improve targeted 36 photoactivity of Verteporfin in cancer cells Inhibition of autophagosome formation by the benzoporphyrin derivative 39 verteporfin Clinical pharmacokinetics of verteporfin The study was supported by the National Science and Technology Major Project The authors declare no competing interests.